Enhancement of Tumor Response to -Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme
- 1 September 1999
- journal article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 91 (17), 1501-1504
- https://doi.org/10.1093/jnci/91.17.1501
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Inhibition of Metastases by AnticoagulantsJNCI Journal of the National Cancer Institute, 1999
- Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part II)JNCI Journal of the National Cancer Institute, 1998
- Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part I)JNCI Journal of the National Cancer Institute, 1998
- Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2Science, 1998
- Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)Journal of Medicinal Chemistry, 1997
- CYCLOOXYGENASE-2 INHIBITORS: A New Class of Anti-Inflammatory Agents That Spare the Gastrointestinal TractGastroenterology Clinics of North America, 1996
- Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.Proceedings of the National Academy of Sciences, 1994
- Clinical applications of prostaglandins and their inhibitors.Stroke, 1981
- Prostaglandins and cancer: A review of tumor initiation through tumor metastasisProstaglandins, 1981
- Prostaglandin modulation of development of cell-mediated immunity in cultureNature, 1980